drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00222 | DB00328 | 245 | 831 | [
"DDInter825",
"DDInter921"
] | Glimepiride | Indomethacin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Moderate | 1 | [
[
[
245,
24,
831
]
],
[
[
245,
24,
535
],
[
535,
40,
831
]
],
[
[
245,
24,
1263
],
[
1263,
1,
831
]
],
[
[
245,
6,
6017
],
[
6017,
4... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Fenofibrate and Fenofibrate (Compound) resembles Indomethacin (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac (Compound) resembles Indomethacin (Comp... |
DB01083 | DB01097 | 1,142 | 1,377 | [
"DDInter1348",
"DDInter1033"
] | Orlistat | Leflunomide | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1142,
25,
1377
]
],
[
[
1142,
21,
28701
],
[
28701,
60,
1377
]
],
[
[
1142,
62,
1461
],
[
1461,
23,
1377
]
],
[
[
1142,
24,
242
],
[
2... | [
[
[
"Orlistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Orlistat",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is caused by {v} (Compo... | Orlistat (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Leflunomide (Compound)
Orlistat may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Leflunomide
Or... |
DB00092 | DB00957 | 58 | 873 | [
"DDInter40",
"DDInter1314"
] | Alefacept | Norgestimate | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat mod... | Moderate | 1 | [
[
[
58,
24,
873
]
],
[
[
58,
24,
566
],
[
566,
1,
873
]
],
[
[
58,
63,
1057
],
[
1057,
24,
873
]
],
[
[
58,
24,
1531
],
[
1531,
63,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestimate"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
],
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Norgestimate (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction th... |
DB00533 | DB00687 | 1,416 | 870 | [
"DDInter1613",
"DDInter747"
] | Rofecoxib | Fludrocortisone | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
1416,
24,
870
]
],
[
[
1416,
24,
1220
],
[
1220,
40,
870
]
],
[
[
1416,
63,
251
],
[
251,
40,
870
]
],
[
[
1416,
63,
1018
],
[
1018,
... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Fludroc... |
DB00448 | DB01175 | 1,215 | 318 | [
"DDInter1022",
"DDInter672"
] | Lansoprazole | Escitalopram | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
1215,
24,
318
]
],
[
[
1215,
64,
1230
],
[
1230,
1,
318
]
],
[
[
1215,
6,
8374
],
[
8374,
45,
318
]
],
[
[
1215,
21,
29461
],
[
29461,... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Lansoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Cita... | Lansoprazole may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Lansoprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Lansoprazole (Compound) causes Dysmenorrhoea (Side Effect) and Dysmenorrh... |
DB00424 | DB00647 | 19 | 675 | [
"DDInter896",
"DDInter528"
] | Hyoscyamine | Dextropropoxyphene | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Moderate | 1 | [
[
[
19,
24,
675
]
],
[
[
19,
63,
494
],
[
494,
1,
675
]
],
[
[
19,
24,
1511
],
[
1511,
63,
675
]
],
[
[
19,
24,
1301
],
[
1301,
40,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Dextropropoxyphene (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate intera... |
DB00810 | DB06282 | 456 | 516 | [
"DDInter211",
"DDInter1053"
] | Biperiden | Levocetirizine | A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
456,
24,
516
]
],
[
[
456,
63,
701
],
[
701,
24,
516
]
],
[
[
456,
24,
407
],
[
407,
63,
516
]
],
[
[
456,
24,
649
],
[
649,
24,... | [
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
... | Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may... |
DB00835 | DB13913 | 100 | 1,536 | [
"DDInter245",
"DDInter175"
] | Brompheniramine | Belladonna | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family _Solanaceae_. Its roots, leaves and fruits contain , , and mostly, . These alkaloids are naturally-occurring muscarinic antagonists. is a non-selective muscarinic antagonist that is mainly used as ... | Moderate | 1 | [
[
[
100,
24,
1536
]
],
[
[
100,
35,
849
],
[
849,
24,
1536
]
],
[
[
100,
63,
128
],
[
128,
24,
1536
]
],
[
[
100,
24,
104
],
[
104,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases wh... | Brompheniramine (Compound) resembles Mepyramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Brompheniramine may cause a moderate interac... |
DB00408 | DB00719 | 1,408 | 1,219 | [
"DDInter1099",
"DDInter149"
] | Loxapine | Azatadine | An antipsychotic agent used in schizophrenia. [PubChem] | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
1408,
35,
1219
]
],
[
[
1408,
40,
11287
],
[
11287,
1,
1219
]
],
[
[
1408,
35,
13
],
[
13,
24,
1219
]
],
[
[
1408,
24,
830
],
[
830,
... | [
[
[
"Loxapine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Loxapine",
"{u} (Compound) resembles {v} (Compound)",
"Pirenzepine"
],
[
"Pir... | Loxapine (Compound) resembles Azatadine (Compound) and
Loxapine (Compound) resembles Pirenzepine (Compound) and Pirenzepine (Compound) resembles Azatadine (Compound)
Loxapine (Compound) resembles Cyproheptadine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Cypro... |
DB00467 | DB06335 | 1,467 | 761 | [
"DDInter644",
"DDInter1646"
] | Enoxacin | Saxagliptin | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1467,
24,
761
]
],
[
[
1467,
25,
1573
],
[
1573,
24,
761
]
],
[
[
1467,
25,
1296
],
[
1296,
63,
761
]
],
[
[
1467,
64,
1179
],
[
1179,... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
],
[
"Prednisone",
... | Enoxacin may lead to a major life threatening interaction when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Enoxacin may lead to a major life threatening interaction when taken with Insulin degludec and Insulin degludec may cause a mode... |
DB00486 | DB01089 | 1,614 | 1,340 | [
"DDInter1253",
"DDInter502"
] | Nabilone | Deserpidine | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. | Moderate | 1 | [
[
[
1614,
24,
1340
]
],
[
[
1614,
63,
1245
],
[
1245,
40,
1340
]
],
[
[
1614,
24,
1264
],
[
1264,
63,
1340
]
],
[
[
1614,
24,
1376
],
[
13... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deserpidine"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reserpine"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine (Compound) resembles Deserpidine (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate... |
DB00682 | DB00911 | 126 | 458 | [
"DDInter1951",
"DDInter1811"
] | Warfarin | Tinidazole | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Moderate | 1 | [
[
[
126,
24,
458
]
],
[
[
126,
25,
112
],
[
112,
1,
458
]
],
[
[
126,
6,
8374
],
[
8374,
45,
458
]
],
[
[
126,
63,
752
],
[
752,
23,... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Warfarin may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole (Compound) resembles Tinidazole (Compound)
Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tinidazole (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when t... |
DB00398 | DB04948 | 79 | 1,084 | [
"DDInter1702",
"DDInter1083"
] | Sorafenib | Lofexidine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
79,
24,
1084
]
],
[
[
79,
18,
5871
],
[
5871,
46,
1084
]
],
[
[
79,
23,
112
],
[
112,
23,
1084
]
],
[
[
79,
63,
618
],
[
618,
24... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Sorafenib",
"{u} (Compound) downregulates {v} (Gene)",
"HMGA2"
],
[
"HMGA2",
"{u} (Gene) is upregulated by {v} (C... | Sorafenib (Compound) downregulates HMGA2 (Gene) and HMGA2 (Gene) is upregulated by Lofexidine (Compound)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Sorafe... |
DB00397 | DB01403 | 1,466 | 9 | [
"DDInter1458",
"DDInter1175"
] | Phenylpropanolamine | Methotrimeprazine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
1466,
24,
9
]
],
[
[
1466,
24,
1178
],
[
1178,
40,
9
]
],
[
[
1466,
24,
1164
],
[
1164,
1,
9
]
],
[
[
1466,
24,
401
],
[
401,
24... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tr... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Com... |
DB01168 | DB01244 | 1,053 | 762 | [
"DDInter1526",
"DDInter192"
] | Procarbazine | Bepridil | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Moderate | 1 | [
[
[
1053,
24,
762
]
],
[
[
1053,
63,
1376
],
[
1376,
24,
762
]
],
[
[
1053,
64,
704
],
[
704,
1,
762
]
],
[
[
1053,
63,
832
],
[
832,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Procarbazine may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (C... |
DB00570 | DB11793 | 147 | 738 | [
"DDInter1936",
"DDInter1297"
] | Vinblastine | Niraparib | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
147,
24,
738
]
],
[
[
147,
24,
1213
],
[
1213,
24,
738
]
],
[
[
147,
24,
1033
],
[
1033,
63,
738
]
],
[
[
147,
63,
663
],
[
663,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisi... |
DB00261 | DB00370 | 702 | 1,251 | [
"DDInter93",
"DDInter1230"
] | Anagrelide | Mirtazapine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Major | 2 | [
[
[
702,
25,
1251
]
],
[
[
702,
6,
7950
],
[
7950,
45,
1251
]
],
[
[
702,
21,
31063
],
[
31063,
60,
1251
]
],
[
[
702,
23,
112
],
[
112,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mirtazapine"
]
],
[
[
"Anagrelide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Mirtaz... | Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Mirtazapine (Compound)
Anagrelide (Compound) causes Cardiomegaly (Side Effect) and Cardiomegaly (Side Effect) is caused by Mirtazapine (Compound)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole... |
DB08826 | DB11793 | 1,292 | 738 | [
"DDInter489",
"DDInter1297"
] | Deferiprone | Niraparib | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Major | 2 | [
[
[
1292,
25,
738
]
],
[
[
1292,
64,
1213
],
[
1213,
24,
738
]
],
[
[
1292,
25,
1619
],
[
1619,
63,
738
]
],
[
[
1292,
24,
1017
],
[
1017,... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} ma... | Deferiprone may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Deferiprone may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interac... |
DB00683 | DB14723 | 1,382 | 159 | [
"DDInter1212",
"DDInter1026"
] | Midazolam | Larotrectinib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1382,
24,
159
]
],
[
[
1382,
24,
222
],
[
222,
23,
159
]
],
[
[
1382,
24,
98
],
[
98,
24,
159
]
],
[
[
1382,
1,
481
],
[
481,
24... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatre... |
DB06723 | DB09154 | 115 | 1,475 | [
"DDInter58",
"DDInter1686"
] | Aluminum hydroxide | Sodium citrate | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Major | 2 | [
[
[
115,
25,
1475
]
],
[
[
115,
62,
1603
],
[
1603,
23,
1475
]
],
[
[
115,
23,
1468
],
[
1468,
23,
1475
]
],
[
[
115,
63,
1411
],
[
1411,
... | [
[
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium citrate"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Captopril"
],
[
... | Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Captopril and Captopril may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Ponatinib... |
DB01319 | DB06603 | 34 | 39 | [
"DDInter777",
"DDInter1387"
] | Fosamprenavir | Panobinostat | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
34,
24,
39
]
],
[
[
34,
64,
455
],
[
455,
24,
39
]
],
[
[
34,
1,
1091
],
[
1091,
24,
39
]
],
[
[
34,
24,
578
],
[
578,
63,
... | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Sa... | Fosamprenavir may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Fosamprenavir (Compound) resembles Amprenavir (Compound) and Amprenavir may cause a moderate interaction that could exacer... |
DB00078 | DB01030 | 1,172 | 869 | [
"DDInter898",
"DDInter1835"
] | Ibritumomab tiuxetan | Topotecan | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
1172,
24,
869
]
],
[
[
1172,
24,
1270
],
[
1270,
63,
869
]
],
[
[
1172,
63,
1184
],
[
1184,
24,
869
]
],
[
[
1172,
24,
599
],
[
599,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tubercul... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Ibritumomab tiuxetan may cause a moderate inter... |
DB00494 | DB01233 | 1,533 | 1,311 | [
"DDInter646",
"DDInter1197"
] | Entacapone | Metoclopramide | Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa conce... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1533,
24,
1311
]
],
[
[
1533,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1533,
24,
649
],
[
649,
63,
1311
]
],
[
[
1533,
24,
662
],
[
662... | [
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Entacapone",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) i... | Entacapone (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with M... |
DB00290 | DB11627 | 329 | 1,367 | [
"DDInter219",
"DDInter860"
] | Bleomycin | Hepatitis B Vaccine (Recombinant) | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
329,
24,
1367
]
],
[
[
329,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
329,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
329,
24,
259
],
[
259,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesl... | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Bleomycin may lead to a major life threatening interaction when taken with Cladribine an... |
DB00418 | DB06691 | 536 | 849 | [
"DDInter1650",
"DDInter1155"
] | Secobarbital | Mepyramine | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
536,
24,
849
]
],
[
[
536,
63,
1594
],
[
1594,
24,
849
]
],
[
[
536,
24,
272
],
[
272,
24,
849
]
],
[
[
536,
40,
1023
],
[
1023,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine ... |
DB00443 | DB00754 | 251 | 157 | [
"DDInter195",
"DDInter696"
] | Betamethasone | Ethotoin | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Moderate | 1 | [
[
[
251,
24,
157
]
],
[
[
251,
24,
759
],
[
759,
40,
157
]
],
[
[
251,
7,
7248
],
[
7248,
46,
157
]
],
[
[
251,
18,
6351
],
[
6351,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Betamethasone (Compound) upregulates RPP38 (Gene) and RPP38 (Gene) is upregulated by Ethotoin (Compound)
Betamethasone (Compound) downregulates COTL1 (Gene) and ... |
DB00312 | DB01181 | 1,023 | 1,532 | [
"DDInter1423",
"DDInter906"
] | Pentobarbital | Ifosfamide | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1023,
24,
1532
]
],
[
[
1023,
6,
8717
],
[
8717,
45,
1532
]
],
[
[
1023,
21,
28893
],
[
28893,
60,
1532
]
],
[
[
1023,
63,
1648
],
[
1... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compo... | Pentobarbital (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Ifosfamide (Compound)
Pentobarbital (Compound) causes Hallucination (Side Effect) and Hallucination (Side Effect) is caused by Ifosfamide (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Al... |
DB01069 | DB01320 | 401 | 651 | [
"DDInter1533",
"DDInter783"
] | Promethazine | Fosphenytoin | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
401,
24,
651
]
],
[
[
401,
63,
362
],
[
362,
1,
651
]
],
[
[
401,
6,
6017
],
[
6017,
45,
651
]
],
[
[
401,
21,
28691
],
[
28691,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Promethazine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fosphenytoin (Compound)
Promethazine (Compound) causes Somnolence (Side Effect) and ... |
DB08893 | DB12010 | 271 | 214 | [
"DDInter1229",
"DDInter785"
] | Mirabegron | Fostamatinib | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
271,
24,
214
]
],
[
[
271,
62,
723
],
[
723,
24,
214
]
],
[
[
271,
23,
1017
],
[
1017,
63,
214
]
],
[
[
271,
24,
119
],
[
119,
2... | [
[
[
"Mirabegron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
],
[
... | Mirabegron may cause a minor interaction that can limit clinical effects when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lorlatinib and Lorlatin... |
DB06210 | DB11978 | 72 | 124 | [
"DDInter631",
"DDInter822"
] | Eltrombopag | Glasdegib | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
72,
24,
124
]
],
[
[
72,
24,
466
],
[
466,
62,
124
]
],
[
[
72,
24,
829
],
[
829,
63,
124
]
],
[
[
72,
25,
1339
],
[
1339,
63,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant and Ubr... |
DB00377 | DB04946 | 1,494 | 924 | [
"DDInter1382",
"DDInter907"
] | Palonosetron | Iloperidone | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
1494,
25,
924
]
],
[
[
1494,
24,
1664
],
[
1664,
1,
924
]
],
[
[
1494,
25,
1425
],
[
1425,
25,
924
]
],
[
[
1494,
24,
519
],
[
519,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risp... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when... |
DB00631 | DB00781 | 372 | 1,481 | [
"DDInter405",
"DDInter1489"
] | Clofarabine | Polymyxin B | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Moderate | 1 | [
[
[
372,
24,
1481
]
],
[
[
372,
63,
1441
],
[
1441,
40,
1481
]
],
[
[
372,
21,
28719
],
[
28719,
60,
1481
]
],
[
[
372,
63,
91
],
[
91,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polymyxin B"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacitracin"
],
[... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) resembles Polymyxin B (Compound)
Clofarabine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Polymyxin B (Compound)
Clofarabine may cause a moderate interaction that ... |
DB00539 | DB00816 | 11 | 1,674 | [
"DDInter1837",
"DDInter1346"
] | Toremifene | Orciprenaline | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Major | 2 | [
[
[
11,
25,
1674
]
],
[
[
11,
18,
8355
],
[
8355,
46,
1674
]
],
[
[
11,
7,
16549
],
[
16549,
57,
1674
]
],
[
[
11,
21,
28921
],
[
28921,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
]
],
[
[
"Toremifene",
"{u} (Compound) downregulates {v} (Gene)",
"DPH2"
],
[
"DPH2",
"{u} (Gene) is upregulated by {v} (Compound)",
... | Toremifene (Compound) downregulates DPH2 (Gene) and DPH2 (Gene) is upregulated by Orciprenaline (Compound)
Toremifene (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is downregulated by Orciprenaline (Compound)
Toremifene (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orcipren... |
DB00911 | DB08904 | 458 | 375 | [
"DDInter1811",
"DDInter342"
] | Tinidazole | Certolizumab pegol | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
458,
24,
375
]
],
[
[
458,
63,
231
],
[
231,
24,
375
]
],
[
[
458,
24,
1047
],
[
1047,
24,
375
]
],
[
[
458,
24,
1434
],
[
1434,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
],
... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emt... |
DB05316 | DB05812 | 749 | 1,374 | [
"DDInter1467",
"DDInter8"
] | Pimavanserin | Abiraterone | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
749,
24,
1374
]
],
[
[
749,
62,
112
],
[
112,
23,
1374
]
],
[
[
749,
25,
760
],
[
760,
62,
1374
]
],
[
[
749,
63,
1494
],
[
1494,
... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Pimavanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Pimavanserin may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may... |
DB11760 | DB12010 | 119 | 214 | [
"DDInter1742",
"DDInter785"
] | Talazoparib | Fostamatinib | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
119,
24,
214
]
],
[
[
119,
64,
976
],
[
976,
24,
214
]
],
[
[
119,
63,
597
],
[
597,
24,
214
]
],
[
[
119,
24,
738
],
[
738,
24,... | [
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Talazoparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofac... | Talazoparib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphe... |
DB01174 | DB08880 | 697 | 1,510 | [
"DDInter1442",
"DDInter1771"
] | Phenobarbital | Teriflunomide | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
697,
24,
1510
]
],
[
[
697,
62,
608
],
[
608,
23,
1510
]
],
[
[
697,
24,
129
],
[
129,
63,
1510
]
],
[
[
697,
25,
1033
],
[
1033,
... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Phenobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
... | Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and E... |
DB00377 | DB09472 | 1,494 | 1,383 | [
"DDInter1382",
"DDInter1693"
] | Palonosetron | Sodium sulfate | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1494,
24,
1383
]
],
[
[
1494,
24,
609
],
[
609,
24,
1383
]
],
[
[
1494,
25,
643
],
[
643,
24,
1383
]
],
[
[
1494,
63,
521
],
[
521,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Palonosetron may lead to a major life threatening interaction when taken with Desvenlafaxine and D... |
DB06650 | DB10989 | 1,500 | 496 | [
"DDInter1324",
"DDInter858"
] | Ofatumumab | Hepatitis A Vaccine | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
1500,
24,
496
]
],
[
[
1500,
63,
4
],
[
4,
24,
496
]
],
[
[
1500,
24,
738
],
[
738,
63,
496
]
],
[
[
1500,
25,
976
],
[
976,
24,... | [
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesu... | Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Ofatumumab may cause a moderate interaction that could exacerbate disease... |
DB01611 | DB08899 | 1,487 | 129 | [
"DDInter893",
"DDInter649"
] | Hydroxychloroquine | Enzalutamide | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1487,
24,
129
]
],
[
[
1487,
63,
918
],
[
918,
1,
129
]
],
[
[
1487,
6,
12523
],
[
12523,
45,
129
]
],
[
[
1487,
21,
28703
],
[
28703,... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutam... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Hydroxychloroquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Enzalutamide (Compound)
Hydroxychloroquine (Compound) causes Pruri... |
DB00026 | DB00619 | 1,184 | 1,419 | [
"DDInter94",
"DDInter909"
] | Anakinra | Imatinib | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
1184,
24,
1419
]
],
[
[
1184,
24,
1101
],
[
1101,
23,
1419
]
],
[
[
1184,
24,
309
],
[
309,
63,
1419
]
],
[
[
1184,
24,
599
],
[
599,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"B... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Imatinib
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone m... |
DB00421 | DB06616 | 443 | 594 | [
"DDInter1707",
"DDInter224"
] | Spironolactone | Bosutinib | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
443,
24,
594
]
],
[
[
443,
6,
4973
],
[
4973,
45,
594
]
],
[
[
443,
18,
1870
],
[
1870,
57,
594
]
],
[
[
443,
21,
28882
],
[
28882,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Spironolactone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compou... | Spironolactone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Bosutinib (Compound)
Spironolactone (Compound) downregulates MYC (Gene) and MYC (Gene) is downregulated by Bosutinib (Compound)
Spironolactone (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect)... |
DB00063 | DB12364 | 366 | 1,421 | [
"DDInter659",
"DDInter200"
] | Eptifibatide | Betrixaban | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
366,
25,
1421
]
],
[
[
366,
23,
297
],
[
297,
23,
1421
]
],
[
[
366,
23,
1631
],
[
1631,
62,
1421
]
],
[
[
366,
24,
992
],
[
992,
... | [
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Eptifibatide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
... | Eptifibatide may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Eptifibatide may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a... |
DB00991 | DB04865 | 97 | 4 | [
"DDInter1358",
"DDInter1335"
] | Oxaprozin | Omacetaxine mepesuccinate | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
97,
25,
4
]
],
[
[
97,
6,
7720
],
[
7720,
46,
4
]
],
[
[
97,
63,
1645
],
[
1645,
24,
4
]
],
[
[
97,
24,
617
],
[
617,
24,
... | [
[
[
"Oxaprozin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Oxaprozin",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)... | Oxaprozin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine me... |
DB00075 | DB01097 | 541 | 1,377 | [
"DDInter1250",
"DDInter1033"
] | Muromonab | Leflunomide | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
541,
25,
1377
]
],
[
[
541,
23,
1461
],
[
1461,
23,
1377
]
],
[
[
541,
23,
1193
],
[
1193,
62,
1377
]
],
[
[
541,
24,
949
],
[
949,
... | [
[
[
"Muromonab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Muromonab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Muromonab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Leflunomide
Muromonab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc glucon... |
DB01254 | DB01319 | 1,213 | 34 | [
"DDInter484",
"DDInter777"
] | Dasatinib | Fosamprenavir | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Major | 2 | [
[
[
1213,
25,
34
]
],
[
[
1213,
64,
1091
],
[
1091,
40,
34
]
],
[
[
1213,
6,
8374
],
[
8374,
45,
34
]
],
[
[
1213,
21,
29062
],
[
29062,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} ... | Dasatinib may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Dasatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Dasatinib (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side E... |
DB00598 | DB01364 | 1,523 | 22 | [
"DDInter1013",
"DDInter650"
] | Labetalol | Ephedrine | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
1523,
24,
22
]
],
[
[
1523,
40,
838
],
[
838,
1,
22
]
],
[
[
1523,
24,
1445
],
[
1445,
1,
22
]
],
[
[
1523,
6,
3576
],
[
3576,
4... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Isoxsuprine"
],
[
"Isoxsuprine",
"{u} (Compound) resembles... | Labetalol (Compound) resembles Isoxsuprine (Compound) and Isoxsuprine (Compound) resembles Ephedrine (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Ephedrine (Compound)
Labetalol (Compound) binds ADRB2 (Gene) ... |
DB00357 | DB15328 | 1,051 | 829 | [
"DDInter71",
"DDInter1896"
] | Aminoglutethimide | Ubrogepant | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
1051,
24,
829
]
],
[
[
1051,
24,
1476
],
[
1476,
24,
829
]
],
[
[
1051,
63,
883
],
[
883,
24,
829
]
],
[
[
1051,
62,
1101
],
[
1101,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Gefitin... |
DB08815 | DB09472 | 154 | 1,383 | [
"DDInter1104",
"DDInter1693"
] | Lurasidone | Sodium sulfate | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
154,
24,
1383
]
],
[
[
154,
64,
609
],
[
609,
24,
1383
]
],
[
[
154,
24,
971
],
[
971,
63,
1383
]
],
[
[
154,
63,
392
],
[
392,
... | [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Lurasidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Cl... | Lurasidone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteri... |
DB00011 | DB08895 | 1,451 | 976 | [
"DDInter944",
"DDInter1825"
] | Interferon alfa-n1 | Tofacitinib | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1451,
25,
976
]
],
[
[
1451,
25,
534
],
[
534,
24,
976
]
],
[
[
1451,
24,
1430
],
[
1430,
24,
976
]
],
[
[
1451,
24,
810
],
[
810,
... | [
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",... | Interferon alfa-n1 may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipule... |
DB01169 | DB01599 | 57 | 1,232 | [
"DDInter120",
"DDInter1523"
] | Arsenic trioxide | Probucol | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Major | 2 | [
[
[
57,
25,
1232
]
],
[
[
57,
62,
112
],
[
112,
23,
1232
]
],
[
[
57,
64,
1555
],
[
1555,
24,
1232
]
],
[
[
57,
25,
927
],
[
927,
63... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Probucol"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Probucol
Arsenic trioxide may lead to a major life threatening interaction when taken with Oxaliplatin and Oxalipla... |
DB09280 | DB11642 | 1,604 | 938 | [
"DDInter1101",
"DDInter1480"
] | Lumacaftor | Pitolisant | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Major | 2 | [
[
[
1604,
25,
938
]
],
[
[
1604,
63,
473
],
[
473,
24,
938
]
],
[
[
1604,
64,
978
],
[
978,
24,
938
]
],
[
[
1604,
25,
927
],
[
927,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglini... | Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Lumacaftor may lead to a major life threatening interaction when taken with Praziquantel and Praziquantel may ... |
DB00719 | DB01175 | 1,219 | 318 | [
"DDInter149",
"DDInter672"
] | Azatadine | Escitalopram | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
1219,
24,
318
]
],
[
[
1219,
63,
1230
],
[
1230,
1,
318
]
],
[
[
1219,
6,
8374
],
[
8374,
45,
318
]
],
[
[
1219,
24,
1376
],
[
1376,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Azatadine may cause a moderate interaction that could exacerbate... |
DB08901 | DB11003 | 1,468 | 748 | [
"DDInter1492",
"DDInter100"
] | Ponatinib | Anthrax vaccine | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1468,
24,
748
]
],
[
[
1468,
63,
322
],
[
322,
24,
748
]
],
[
[
1468,
25,
676
],
[
676,
63,
748
]
],
[
[
1468,
24,
1619
],
[
1619,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ponatinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may... |
DB00860 | DB00983 | 891 | 480 | [
"DDInter1513",
"DDInter776"
] | Prednisolone | Formoterol | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Minor | 0 | [
[
[
891,
23,
480
]
],
[
[
891,
23,
1148
],
[
1148,
63,
480
]
],
[
[
891,
63,
1523
],
[
1523,
25,
480
]
],
[
[
891,
5,
11566
],
[
11566,
... | [
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoprenaline"
],
[
... | Prednisolone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and L... |
DB00656 | DB09104 | 827 | 286 | [
"DDInter1851",
"DDInter1118"
] | Trazodone | Magnesium hydroxide | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
827,
24,
286
]
],
[
[
827,
24,
820
],
[
820,
23,
286
]
],
[
[
827,
63,
999
],
[
999,
23,
286
]
],
[
[
827,
24,
688
],
[
688,
24,... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazi... |
DB01064 | DB08882 | 1,148 | 1,281 | [
"DDInter987",
"DDInter1070"
] | Isoprenaline | Linagliptin | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1148,
24,
1281
]
],
[
[
1148,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
1148,
21,
28762
],
[
28762,
60,
1281
]
],
[
[
1148,
24,
1529
],
[
1... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Isoprenaline (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Linagliptin (Compound)
Isoprenaline may cause a moderate intera... |
DB00496 | DB01619 | 194 | 830 | [
"DDInter480",
"DDInter1441"
] | Darifenacin | Phenindamine | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
194,
24,
830
]
],
[
[
194,
24,
537
],
[
537,
40,
830
]
],
[
[
194,
63,
13
],
[
13,
24,
830
]
],
[
[
194,
24,
104
],
[
104,
1,
... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction ... |
DB00364 | DB01390 | 417 | 1,117 | [
"DDInter1717",
"DDInter1683"
] | Sucralfate | Sodium bicarbonate | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Moderate | 1 | [
[
[
417,
24,
1117
]
],
[
[
417,
21,
28882
],
[
28882,
60,
1117
]
],
[
[
417,
24,
954
],
[
954,
23,
1117
]
],
[
[
417,
24,
1482
],
[
1482,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Sucralfate",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature in... | Sucralfate (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sodium bicarbonate (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit cl... |
DB08871 | DB14711 | 36 | 779 | [
"DDInter666",
"DDInter1680"
] | Eribulin | Smallpox (Vaccinia) Vaccine, Live | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
36,
25,
779
]
],
[
[
36,
64,
1064
],
[
1064,
25,
779
]
],
[
[
36,
63,
147
],
[
147,
25,
779
]
],
[
[
36,
25,
1259
],
[
1259,
25,... | [
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladri... | Eribulin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may ... |
DB01285 | DB11827 | 708 | 433 | [
"DDInter445",
"DDInter669"
] | Corticotropin | Ertugliflozin | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
708,
24,
433
]
],
[
[
708,
63,
1020
],
[
1020,
24,
433
]
],
[
[
708,
24,
35
],
[
35,
24,
433
]
],
[
[
708,
62,
688
],
[
688,
24,... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and... |
DB00750 | DB06608 | 490 | 1,185 | [
"DDInter1518",
"DDInter1739"
] | Prilocaine | Tafenoquine | A local anesthetic that is similar pharmacologically to lidocaine. Currently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165) | Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoq... | Major | 2 | [
[
[
490,
25,
1185
]
],
[
[
490,
64,
10
],
[
10,
24,
1185
]
],
[
[
490,
25,
1455
],
[
1455,
64,
1185
]
],
[
[
490,
64,
10
],
[
10,
25... | [
[
[
"Prilocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tafenoquine"
]
],
[
[
"Prilocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may ca... | Prilocaine may lead to a major life threatening interaction when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Tafenoquine
Prilocaine may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life t... |
DB00604 | DB00697 | 1,425 | 876 | [
"DDInter385",
"DDInter1821"
] | Cisapride | Tizanidine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Major | 2 | [
[
[
1425,
25,
876
]
],
[
[
1425,
6,
7950
],
[
7950,
45,
876
]
],
[
[
1425,
23,
112
],
[
112,
62,
876
]
],
[
[
1425,
25,
401
],
[
401,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Tizanidin... | Cisapride (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tizanidine (Compound)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tizanidine
Cisapride may lead... |
DB00016 | DB08889 | 787 | 350 | [
"DDInter671",
"DDInter299"
] | Erythropoietin | Carfilzomib | Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commerc... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Major | 2 | [
[
[
787,
25,
350
]
],
[
[
787,
25,
770
],
[
770,
24,
350
]
],
[
[
787,
24,
687
],
[
687,
64,
350
]
],
[
[
787,
24,
1514
],
[
1514,
2... | [
[
[
"Erythropoietin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
],
[
[
"Erythropoietin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
... | Erythropoietin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Erythropoietin may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa and Conesta... |
DB04845 | DB15093 | 309 | 1,654 | [
"DDInter1001",
"DDInter1698"
] | Ixabepilone | Somapacitan | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
309,
24,
1654
]
],
[
[
309,
63,
168
],
[
168,
23,
1654
]
],
[
[
309,
63,
10
],
[
10,
24,
1654
]
],
[
[
309,
24,
351
],
[
351,
24... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone ... |
DB00414 | DB01377 | 590 | 1,283 | [
"DDInter16",
"DDInter1119"
] | Acetohexamide | Magnesium oxide | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Moderate | 1 | [
[
[
590,
24,
1283
]
],
[
[
590,
24,
743
],
[
743,
23,
1283
]
],
[
[
590,
63,
461
],
[
461,
23,
1283
]
],
[
[
590,
24,
1592
],
[
1592,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Timolol and ... |
DB00250 | DB00444 | 10 | 63 | [
"DDInter475",
"DDInter1765"
] | Dapsone | Teniposide | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Moderate | 1 | [
[
[
10,
24,
63
]
],
[
[
10,
6,
6017
],
[
6017,
45,
63
]
],
[
[
10,
6,
7720
],
[
7720,
46,
63
]
],
[
[
10,
21,
28900
],
[
28900,
60,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Dapsone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Teniposide (Compound)
Dapsone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Teniposide (Compound)
Dapsone (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Teniposide (Compound)
Dapsone may... |
DB00574 | DB06702 | 121 | 573 | [
"DDInter717",
"DDInter731"
] | Fenfluramine | Fesoterodine | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
121,
24,
573
]
],
[
[
121,
23,
211
],
[
211,
1,
573
]
],
[
[
121,
63,
1018
],
[
1018,
24,
573
]
],
[
[
121,
25,
1039
],
[
1039,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Fenfluramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
],
... | Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction th... |
DB01259 | DB14730 | 392 | 1,412 | [
"DDInter1024",
"DDInter264"
] | Lapatinib | Calaspargase pegol | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
392,
24,
1412
]
],
[
[
392,
24,
792
],
[
792,
24,
1412
]
],
[
[
392,
63,
1347
],
[
1347,
24,
1412
]
],
[
[
392,
74,
883
],
[
883,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel a... |
DB01064 | DB01611 | 1,148 | 1,487 | [
"DDInter987",
"DDInter893"
] | Isoprenaline | Hydroxychloroquine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1148,
24,
1487
]
],
[
[
1148,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
1148,
21,
28817
],
[
28817,
60,
1487
]
],
[
[
1148,
63,
88
],
[
88... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Isoprenaline (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Hydroxychlo... |
DB00365 | DB12245 | 839 | 823 | [
"DDInter842",
"DDInter1863"
] | Grepafloxacin | Triclabendazole | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
839,
25,
823
]
],
[
[
839,
23,
112
],
[
112,
23,
823
]
],
[
[
839,
64,
1010
],
[
1010,
24,
823
]
],
[
[
839,
24,
28
],
[
28,
24,... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Grepafloxacin may lead to a major life threatening interaction when taken with Mefloquine and Mefloqui... |
DB00682 | DB01276 | 126 | 123 | [
"DDInter1951",
"DDInter706"
] | Warfarin | Exenatide | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
126,
24,
123
]
],
[
[
126,
63,
1463
],
[
1463,
23,
123
]
],
[
[
126,
24,
1072
],
[
1072,
24,
123
]
],
[
[
126,
24,
708
],
[
708,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may ... |
DB00678 | DB01142 | 240 | 1,264 | [
"DDInter1095",
"DDInter593"
] | Losartan | Doxepin | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
240,
24,
1264
]
],
[
[
240,
24,
401
],
[
401,
24,
1264
]
],
[
[
240,
6,
4973
],
[
4973,
45,
1264
]
],
[
[
240,
21,
29226
],
[
29226,
... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"... | Losartan may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Losartan (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound)
Losartan (Compound) causes... |
DB00445 | DB00674 | 322 | 1,516 | [
"DDInter655",
"DDInter802"
] | Epirubicin | Galantamine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Moderate | 1 | [
[
[
322,
24,
1516
]
],
[
[
322,
7,
11074
],
[
11074,
46,
1516
]
],
[
[
322,
21,
28766
],
[
28766,
60,
1516
]
],
[
[
322,
63,
618
],
[
618,... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Galantamine"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"HERC6"
],
[
"HERC6",
"{u} (Gene) is upregulated by {v} (... | Epirubicin (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Galantamine (Compound)
Epirubicin (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Galantamine (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Aba... |
DB00682 | DB01222 | 126 | 617 | [
"DDInter1951",
"DDInter246"
] | Warfarin | Budesonide | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
126,
24,
617
]
],
[
[
126,
63,
251
],
[
251,
1,
617
]
],
[
[
126,
24,
1220
],
[
1220,
1,
617
]
],
[
[
126,
6,
8374
],
[
8374,
45... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (Co... |
DB00559 | DB01006 | 152 | 300 | [
"DDInter223",
"DDInter1040"
] | Bosentan | Letrozole | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Moderate | 1 | [
[
[
152,
24,
300
]
],
[
[
152,
6,
8374
],
[
8374,
45,
300
]
],
[
[
152,
21,
28646
],
[
28646,
60,
300
]
],
[
[
152,
24,
478
],
[
478,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Letrozole"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Letrozole (Compound)
Bosentan (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Letrozole (Compound)
Bosentan may cause a moderate ... |
DB10315 | DB11767 | 1,137 | 1,583 | [
"DDInter1127",
"DDInter1643"
] | Measles virus vaccine live attenuated | Sarilumab | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Major | 2 | [
[
[
1137,
25,
1583
]
],
[
[
1137,
64,
850
],
[
850,
24,
1583
]
],
[
[
1137,
25,
738
],
[
738,
63,
1583
]
],
[
[
1137,
25,
1456
],
[
1456,
... | [
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bren... | Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Measles virus vaccine live attenuated may lead to a major life threatening interact... |
DB10343 | DB11730 | 962 | 351 | [
"DDInter160",
"DDInter1588"
] | Bacillus calmette-guerin substrain tice live antigen | Ribociclib | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
962,
25,
351
]
],
[
[
962,
64,
310
],
[
310,
24,
351
]
],
[
[
962,
25,
738
],
[
738,
63,
351
]
],
[
[
962,
63,
617
],
[
617,
24,... | [
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction wh... | Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threa... |
DB00679 | DB13928 | 684 | 1,385 | [
"DDInter1796",
"DDInter1660"
] | Thioridazine | Semaglutide | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
684,
24,
1385
]
],
[
[
684,
25,
1154
],
[
1154,
24,
1385
]
],
[
[
684,
63,
73
],
[
73,
24,
1385
]
],
[
[
684,
24,
1144
],
[
1144,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasi... | Thioridazine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine m... |
DB00254 | DB01024 | 964 | 1,096 | [
"DDInter598",
"DDInter1252"
] | Doxycycline | Mycophenolic acid | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
964,
24,
1096
]
],
[
[
964,
24,
955
],
[
955,
1,
1096
]
],
[
[
964,
24,
157
],
[
157,
23,
1096
]
],
[
[
964,
24,
428
],
[
428,
6... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofe... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin and Ethotoin may cause a mino... |
DB01128 | DB11703 | 918 | 405 | [
"DDInter204",
"DDInter9"
] | Bicalutamide | Acalabrutinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
918,
24,
405
]
],
[
[
918,
25,
982
],
[
982,
63,
405
]
],
[
[
918,
24,
1313
],
[
1313,
24,
405
]
],
[
[
918,
64,
1230
],
[
1230,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivo... | Bicalutamide may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant and Suvorexant may... |
DB00674 | DB11730 | 1,516 | 351 | [
"DDInter802",
"DDInter1588"
] | Galantamine | Ribociclib | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1516,
24,
351
]
],
[
[
1516,
24,
112
],
[
112,
23,
351
]
],
[
[
1516,
24,
283
],
[
283,
62,
351
]
],
[
[
1516,
24,
98
],
[
98,
2... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and ... |
DB00820 | DB01211 | 402 | 609 | [
"DDInter1736",
"DDInter393"
] | Tadalafil | Clarithromycin | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibito... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
402,
24,
609
]
],
[
[
402,
6,
8374
],
[
8374,
45,
609
]
],
[
[
402,
21,
28759
],
[
28759,
60,
609
]
],
[
[
402,
63,
600
],
[
600,
... | [
[
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Tadalafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Tadalafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound)
Tadalafil (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Clarithromycin (Compound)
Tadalafil may cause a moderate interaction that could exacerbate disea... |
DB08816 | DB12141 | 578 | 971 | [
"DDInter1802",
"DDInter817"
] | Ticagrelor | Gilteritinib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
578,
24,
971
]
],
[
[
578,
23,
1135
],
[
1135,
23,
971
]
],
[
[
578,
24,
1097
],
[
1097,
24,
971
]
],
[
[
578,
63,
1335
],
[
1335,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasmiditan... |
DB00564 | DB11988 | 1,236 | 270 | [
"DDInter293",
"DDInter1321"
] | Carbamazepine | Ocrelizumab | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1236,
24,
270
]
],
[
[
1236,
63,
134
],
[
134,
24,
270
]
],
[
[
1236,
25,
1019
],
[
1019,
24,
270
]
],
[
[
1236,
24,
175
],
[
175,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Carbamazepine may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort... |
DB00719 | DB01238 | 1,219 | 673 | [
"DDInter149",
"DDInter118"
] | Azatadine | Aripiprazole | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
1219,
24,
673
]
],
[
[
1219,
24,
851
],
[
851,
1,
673
]
],
[
[
1219,
63,
827
],
[
827,
40,
673
]
],
[
[
1219,
6,
8374
],
[
8374,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compound)
... |
DB00005 | DB00404 | 1,057 | 523 | [
"DDInter687",
"DDInter54"
] | Etanercept | Alprazolam | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Moderate | 1 | [
[
[
1057,
24,
523
]
],
[
[
1057,
24,
1382
],
[
1382,
1,
523
]
],
[
[
1057,
24,
902
],
[
902,
40,
523
]
],
[
[
1057,
24,
1031
],
[
1031,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
],
[
... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Alprazolam (Compound)
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Alprazolam (Compound)
Etaner... |
DB00445 | DB01169 | 322 | 57 | [
"DDInter655",
"DDInter120"
] | Epirubicin | Arsenic trioxide | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
322,
25,
57
]
],
[
[
322,
7,
2067
],
[
2067,
45,
57
]
],
[
[
322,
23,
1247
],
[
1247,
23,
57
]
],
[
[
322,
24,
480
],
[
480,
24,... | [
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"IKBKB"
],
[
"IKBKB",
"{u} (Gene) is bound by {v} (Compound)",
... | Epirubicin (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Arsenic trioxide (Compound)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Arsenic tri... |
DB00489 | DB01240 | 17 | 885 | [
"DDInter1704",
"DDInter657"
] | Sotalol | Epoprostenol | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
17,
24,
885
]
],
[
[
17,
63,
1061
],
[
1061,
1,
885
]
],
[
[
17,
21,
28936
],
[
28936,
60,
885
]
],
[
[
17,
24,
1512
],
[
1512,
... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
... | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Sotalol (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Epoprostenol (Compound)
Sotalol may cause a moderate inter... |
DB08873 | DB11921 | 74 | 1,019 | [
"DDInter221",
"DDInter492"
] | Boceprevir | Deflazacort | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
74,
25,
1019
]
],
[
[
74,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
74,
63,
761
],
[
761,
24,
1019
]
],
[
[
74,
64,
629
],
[
629,
24... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib"... | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagl... |
DB05679 | DB09330 | 1,683 | 985 | [
"DDInter1907",
"DDInter1352"
] | Ustekinumab | Osimertinib | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1683,
24,
985
]
],
[
[
1683,
63,
168
],
[
168,
23,
985
]
],
[
[
1683,
63,
134
],
[
134,
24,
985
]
],
[
[
1683,
24,
119
],
[
119,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vino... |
DB00434 | DB01221 | 13 | 1,190 | [
"DDInter459",
"DDInter1007"
] | Cyproheptadine | Ketamine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Moderate | 1 | [
[
[
13,
24,
1190
]
],
[
[
13,
6,
2250
],
[
2250,
45,
1190
]
],
[
[
13,
21,
28642
],
[
28642,
60,
1190
]
],
[
[
13,
24,
649
],
[
649,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) binds {v} (Gene)",
"DRD2"
],
[
"DRD2",
"{u} (Gene) is bound by {v} (Compound)... | Cyproheptadine (Compound) binds DRD2 (Gene) and DRD2 (Gene) is bound by Ketamine (Compound)
Cyproheptadine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Ketamine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedan... |
DB01229 | DB05812 | 973 | 1,374 | [
"DDInter1377",
"DDInter8"
] | Paclitaxel | Abiraterone | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
973,
24,
1374
]
],
[
[
973,
6,
10417
],
[
10417,
45,
1374
]
],
[
[
973,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
973,
25,
74
],
[
74,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
... | Paclitaxel (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Abiraterone (Compound)
Paclitaxel (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Paclitaxel may lead to a major life threatening interaction when taken with Boceprevir and Boceprevir ma... |
DB00526 | DB06186 | 1,555 | 1,439 | [
"DDInter1355",
"DDInter969"
] | Oxaliplatin | Ipilimumab | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
1555,
24,
1439
]
],
[
[
1555,
63,
912
],
[
912,
24,
1439
]
],
[
[
1555,
24,
1060
],
[
1060,
63,
1439
]
],
[
[
1555,
24,
267
],
[
267,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
]... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Enf... |
DB08907 | DB09564 | 1,344 | 1,296 | [
"DDInter280",
"DDInter930"
] | Canagliflozin | Insulin degludec | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1344,
24,
1296
]
],
[
[
1344,
63,
274
],
[
274,
23,
1296
]
],
[
[
1344,
62,
1103
],
[
1103,
23,
1296
]
],
[
[
1344,
63,
17
],
[
17,
... | [
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
... | Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Canagliflozin may cause a minor interaction that can limit clinical effects when taken with Amcinonid... |
DB08868 | DB11363 | 1,011 | 1,276 | [
"DDInter737",
"DDInter39"
] | Fingolimod | Alectinib | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
1011,
24,
1276
]
],
[
[
1011,
64,
819
],
[
819,
24,
1276
]
],
[
[
1011,
24,
722
],
[
722,
24,
1276
]
],
[
[
1011,
63,
775
],
[
775,
... | [
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acebutolol"
],
[
"Acebutolol"... | Fingolimod may lead to a major life threatening interaction when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol and Levobetaxolol may c... |
DB00421 | DB09156 | 443 | 777 | [
"DDInter1707",
"DDInter964"
] | Spironolactone | Iopromide | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Moderate | 1 | [
[
[
443,
24,
777
]
],
[
[
443,
63,
1648
],
[
1648,
24,
777
]
],
[
[
443,
24,
1512
],
[
1512,
25,
777
]
],
[
[
443,
63,
1645
],
[
1645,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac a... |
DB00238 | DB15091 | 188 | 676 | [
"DDInter1285",
"DDInter1901"
] | Nevirapine | Upadacitinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
188,
24,
676
]
],
[
[
188,
24,
283
],
[
283,
24,
676
]
],
[
[
188,
63,
600
],
[
600,
24,
676
]
],
[
[
188,
25,
1017
],
[
1017,
2... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Flu... |
DB00557 | DB11837 | 252 | 1,297 | [
"DDInter895",
"DDInter1351"
] | Hydroxyzine | Osilodrostat | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
252,
24,
1297
]
],
[
[
252,
23,
112
],
[
112,
23,
1297
]
],
[
[
252,
24,
222
],
[
222,
23,
1297
]
],
[
[
252,
1,
623
],
[
623,
2... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Hydroxyzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and... |
DB01222 | DB01232 | 617 | 1,327 | [
"DDInter246",
"DDInter1640"
] | Budesonide | Saquinavir | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Major | 2 | [
[
[
617,
25,
1327
]
],
[
[
617,
64,
798
],
[
798,
40,
1327
]
],
[
[
617,
6,
8374
],
[
8374,
45,
1327
]
],
[
[
617,
7,
7972
],
[
7972,
... | [
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} (... | Budesonide may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Budesonide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saquinavir (Compound)
Budesonide (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulate... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.